MX2022002504A - Anticuerpos para cd40. - Google Patents

Anticuerpos para cd40.

Info

Publication number
MX2022002504A
MX2022002504A MX2022002504A MX2022002504A MX2022002504A MX 2022002504 A MX2022002504 A MX 2022002504A MX 2022002504 A MX2022002504 A MX 2022002504A MX 2022002504 A MX2022002504 A MX 2022002504A MX 2022002504 A MX2022002504 A MX 2022002504A
Authority
MX
Mexico
Prior art keywords
antibodies
fcï
riib
bind
administering
Prior art date
Application number
MX2022002504A
Other languages
English (en)
Inventor
Aaron P Yamniuk
Bryan C Barnhart
Brigitte Devaux
Brenda L Stevens
Shannon L Okada
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56322325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022002504(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022002504A publication Critical patent/MX2022002504A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere anticuerpos agonistas, o porciones de unión al antígeno del mismo que se unen a CD40 humano. Tales anticuerpos comprenden opcionalmente regiones Fc con especificidad mejorada para Fc?RIIb. La invención también proporciona métodos para el tratamiento de cáncer o infección crónica administrando los anticuerpos de la invención a un sujeto en necesidad del mismo.
MX2022002504A 2015-06-29 2017-12-13 Anticuerpos para cd40. MX2022002504A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186076P 2015-06-29 2015-06-29
US201562252615P 2015-11-09 2015-11-09

Publications (1)

Publication Number Publication Date
MX2022002504A true MX2022002504A (es) 2022-04-06

Family

ID=56322325

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016253A MX2017016253A (es) 2015-06-29 2016-06-28 Anticuerpos para cd40.
MX2022002504A MX2022002504A (es) 2015-06-29 2017-12-13 Anticuerpos para cd40.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017016253A MX2017016253A (es) 2015-06-29 2016-06-28 Anticuerpos para cd40.

Country Status (17)

Country Link
US (3) US20180142030A1 (es)
EP (1) EP3313880A1 (es)
JP (2) JP7350467B2 (es)
KR (1) KR20180021834A (es)
CN (2) CN115838427A (es)
AU (2) AU2016285913B2 (es)
BR (1) BR112017027549A2 (es)
CA (1) CA2990012A1 (es)
CL (2) CL2017003427A1 (es)
CO (1) CO2018000809A2 (es)
EA (1) EA035268B1 (es)
HK (1) HK1252666A1 (es)
IL (1) IL256499B (es)
MX (2) MX2017016253A (es)
PE (1) PE20180315A1 (es)
WO (1) WO2017004006A1 (es)
ZA (1) ZA201708704B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2683406T (pt) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e utilização dos mesmos
MX2017001864A (es) 2014-08-12 2017-08-02 Alligator Bioscience Ab Tratamientos conjuntos con anticuerpos anti cd40.
AU2016285920A1 (en) * 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
SG11201807677YA (en) 2016-03-04 2018-10-30 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity
EP3468997B1 (en) 2016-06-08 2023-09-13 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
AR111830A1 (es) 2017-05-25 2019-08-21 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
MX2019014375A (es) 2017-06-01 2020-01-23 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
EP3732198A1 (en) 2017-12-27 2020-11-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
CA3094763C (en) * 2018-03-23 2024-01-02 Eli Lilly And Company Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
KR20210033029A (ko) * 2018-07-20 2021-03-25 유큐(베이징) 바이오파마 코., 엘티디 항-cd40 항체 및 그의 용도
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
TW202039558A (zh) 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
KR20210097750A (ko) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
AU2020256828A1 (en) 2019-04-10 2021-11-18 Nankai University Anti-CD40 antibody and use thereof
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
WO2023019129A1 (en) * 2021-08-10 2023-02-16 Apexigen, Inc. Biomarkers for cd40 agonist therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2824278C (en) * 2010-12-20 2022-09-20 The Rockefeller University Modulating agonistic tnfr antibodies
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
MX2016008099A (es) 2013-12-20 2016-10-13 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40.
US11059898B2 (en) 2014-03-24 2021-07-13 Cancer Research Technology Limited Modified antibodies containing modified IGG2 domains which elicit agonist or antagonistic properties and use thereof
US20170233485A1 (en) * 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
SG11201807677YA (en) * 2016-03-04 2018-10-30 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity

Also Published As

Publication number Publication date
US20190248911A1 (en) 2019-08-15
CL2017003427A1 (es) 2018-05-04
US20210054091A1 (en) 2021-02-25
CN115838427A (zh) 2023-03-24
ZA201708704B (en) 2019-08-28
US20180142030A1 (en) 2018-05-24
CN107771184B (zh) 2022-11-01
WO2017004006A1 (en) 2017-01-05
CL2022001189A1 (es) 2023-01-20
EP3313880A1 (en) 2018-05-02
AU2022228155A1 (en) 2022-11-10
HK1252666A1 (zh) 2019-05-31
US10844130B2 (en) 2020-11-24
CO2018000809A2 (es) 2018-04-19
JP7350467B2 (ja) 2023-09-26
PE20180315A1 (es) 2018-02-09
IL256499B (en) 2021-12-01
EA201890175A1 (ru) 2018-06-29
AU2016285913B2 (en) 2022-06-16
KR20180021834A (ko) 2018-03-05
IL256499A (en) 2018-02-28
JP2018526978A (ja) 2018-09-20
JP2022028666A (ja) 2022-02-16
MX2017016253A (es) 2018-04-20
CA2990012A1 (en) 2017-01-05
EA035268B1 (ru) 2020-05-22
AU2016285913A1 (en) 2018-02-15
BR112017027549A2 (pt) 2018-09-11
CN107771184A (zh) 2018-03-06

Similar Documents

Publication Publication Date Title
MX2022002504A (es) Anticuerpos para cd40.
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
NZ739750A (en) Anti-tigit antibodies and methods of use
NZ738008A (en) Tigit-binding agents and uses thereof
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201791485A1 (ru) Анти-cd47-антитела и их применения
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
MX2016013218A (es) Molecula de unión al antígeno trifuncional.
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
MX2018000347A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2014151680A8 (en) Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2015008117A (es) Anticuerpos anti-h7cr.
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.